{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:46:36Z","timestamp":1793115996058,"version":"4.5.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MYC translocations in association with Epstein-Barr virus (EBV) infection are often observed in B-cell lymphomas. A subset of Burkitt lymphoma (BL) expresses EBV latent membrane proteins 1 and 2A (LMP1 and LMP2A) in addition to the typical restricted EBV latent gene expression. EBV-associated diffuse large B-cell lymphoma (DLBCL) typically exhibits latency type II or III and expresses LMP1. Here, we investigate the role of LMP1 in MYC-driven lymphomagenesis in our murine model. \u03bb-MYC mice develop tumors having a \u201cstarry sky\u201d appearance and have abnormal p53 expression that is also observed in human BL. LMP2A\/\u03bb-MYC double-transgenic mice develop tumors significantly faster than mice only expressing MYC. Similar to LMP2A\/\u03bb-MYC mice, LMP1\/\u03bb-MYC mice also have accelerated MYC-driven lymphomagenesis. As observed in LMP2A\/\u03bb-MYC mice, p27kip1 was degraded in LMP1\/\u03bb-MYC pretumor and tumor B cells. Coexpression of LMP1 and LMP2A resulted in the enhancement of B cell proliferation. In contrast to LMP2A, the inhibition of Syk or cyclin-dependant kinase (CDK)4\/6 activity did not effectively inhibit LMP1-mediated MYC lymphomagenesis. Also, in contrast to LMP2A, LMP1 did not lessen abnormal p53 expression in \u03bb-MYC tumors. To investigate the significance of LMP1 expression in human BL development, we reanalyzed RNA sequencing (RNA-Seq) data of primary human BL from previous studies. Interestingly, p53 mutations were less observed in LMP1-expressing BL, although they were not significantly changed by EBV infection, indicating LMP1 may lessen p53 mutations in human primary BL. This suggests that LMP1 effects in EBV-associated human BL vary from what we observe in our murine model. Finally, our studies suggest a novel pathogenic role of LMP1 in lymphomagenesis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007695","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T16:55:40Z","timestamp":1653324940000},"page":"4283-4296","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis"],"prefix":"10.1182","volume":"6","author":[{"given":"Masato","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-0286","authenticated-orcid":false,"given":"Cooper K.","family":"Hayes","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Schaller","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Longnecker","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"2022072215253130900_B1","first-page":"1898","volume-title":"Epstein-Barr Virus. Fields Virology.","author":"Longnecker","year":"2013"},{"issue":"10","key":"2022072215253130900_B2","doi-asserted-by":"crossref","first-page":"e1005158","DOI":"10.1371\/journal.ppat.1005158","article-title":"Distinct viral and mutational spectrum of endemic Burkitt lymphoma","volume":"11","author":"Abate","year":"2015","journal-title":"PLoS Pathog."},{"issue":"4","key":"2022072215253130900_B3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V91.4.1373","article-title":"Epstein-Barr virus (EBV) in endemic Burkitt\u2019s lymphoma: molecular analysis of primary tumor tissue","volume":"91","author":"Tao","year":"1998","journal-title":"Blood."},{"issue":"5","key":"2022072215253130900_B4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.10372","article-title":"Promiscuous expression of Epstein-Barr virus genes in Burkitt\u2019s lymphoma from the central African country Malawi","volume":"99","author":"Xue","year":"2002","journal-title":"Int J Cancer."},{"issue":"Pt 4","key":"2022072215253130900_B5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1099\/vir.0.18687-0","article-title":"Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt\u2019s lymphoma cell lines","volume":"84","author":"Touitou","year":"2003","journal-title":"J Gen Virol."},{"issue":"Pt 10","key":"2022072215253130900_B6","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1099\/vir.0.81906-0","article-title":"Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt\u2019s lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays","volume":"87","author":"Bell","year":"2006","journal-title":"J Gen Virol."},{"key":"2022072215253130900_B7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2014.10.030","article-title":"Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA","volume":"474","author":"Tierney","year":"2015","journal-title":"Virology."},{"issue":"20","key":"2022072215253130900_B8","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood."},{"issue":"5","key":"2022072215253130900_B9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/1541-7786.MCR-16-0305","article-title":"Comprehensive transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences","volume":"15","author":"Kaymaz","year":"2017","journal-title":"Mol Cancer Res."},{"issue":"12","key":"2022072215253130900_B10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood."},{"key":"2022072215253130900_B11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13027-020-00292-w","article-title":"Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program","volume":"15","author":"Granai","year":"2020","journal-title":"Infect Agent Cancer."},{"issue":"02","key":"2022072215253130900_B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4236\/ojpathology.2016.62010","article-title":"LMP1 Immunohistochemistry in non-Hodgkin\u2019s lymphoma of Sudanese cases","volume":"6","author":"Ismail","year":"2016","journal-title":"Open Journal of Pathology."},{"issue":"1","key":"2022072215253130900_B13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-9378-9-34","article-title":"The role of EBV in the pathogenesis of Burkitt\u2019s lymphoma: an Italian hospital based survey","volume":"9","author":"Pannone","year":"2014","journal-title":"Infect Agent Cancer."},{"issue":"2","key":"2022072215253130900_B14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood.V86.2.659.bloodjournal862659","article-title":"Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt\u2019s lymphoma","volume":"86","author":"Niedobitek","year":"1995","journal-title":"Blood."},{"issue":"4","key":"2022072215253130900_B15","first-page":"1072","article-title":"Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin\u2019s lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency","volume":"143","author":"Hamilton-Dutoit","year":"1993","journal-title":"Am J Pathol."},{"issue":"3","key":"2022072215253130900_B16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood.V87.3.1202b.bloodjournal8731202b","article-title":"Expression of Epstein-Barr virus-encoded latent membrane protein 1 in nonendemic Burkitt\u2019s lymphomas","volume":"87","author":"Carbone","year":"1996","journal-title":"Blood."},{"issue":"7","key":"2022072215253130900_B17","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1182\/blood.V77.7.1508.1508","article-title":"Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin\u2019s lymphoma: clinical correlations","volume":"77","author":"Offit","year":"1991","journal-title":"Blood."},{"issue":"3","key":"2022072215253130900_B18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2022072215253130900_B19","first-page":"549","article-title":"The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain","volume":"10","author":"Huen","year":"1995","journal-title":"Oncogene."},{"issue":"12","key":"2022072215253130900_B20","doi-asserted-by":"crossref","first-page":"9908","DOI":"10.1128\/JVI.73.12.9908-9916.1999","article-title":"The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation","volume":"73","author":"Izumi","year":"1999","journal-title":"J Virol."},{"issue":"7","key":"2022072215253130900_B21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0092-8674(90)90695-B","article-title":"Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6","volume":"61","author":"Wilson","year":"1990","journal-title":"Cell."},{"issue":"20","key":"2022072215253130900_B22","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1073\/pnas.95.20.11963","article-title":"Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice","volume":"95","author":"Kulwichit","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"issue":"19","key":"2022072215253130900_B23","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1158\/0008-5472.CAN-05-0591","article-title":"Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9","volume":"65","author":"Stevenson","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"2022072215253130900_B24","doi-asserted-by":"crossref","first-page":"e54010","DOI":"10.1371\/journal.pone.0054010","article-title":"The effect of Epstein-Barr virus latent membrane protein 2 expression on the kinetics of early B cell infection","volume":"8","author":"Wasil","year":"2013","journal-title":"PLoS One."},{"issue":"3","key":"2022072215253130900_B25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity."},{"issue":"2","key":"2022072215253130900_B26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell."},{"issue":"7418","key":"2022072215253130900_B27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature."},{"issue":"12","key":"2022072215253130900_B28","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2022072215253130900_B29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1084\/jem.192.8.1183","article-title":"Burkitt lymphoma in the mouse","volume":"192","author":"Kovalchuk","year":"2000","journal-title":"J Exp Med."},{"issue":"12","key":"2022072215253130900_B30","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1158\/1535-7163.MCT-13-0044","article-title":"Utilization of the E\u03bc-Myc mouse to model heterogeneity of therapeutic response","volume":"13","author":"Rempel","year":"2014","journal-title":"Mol Cancer Ther."},{"issue":"42","key":"2022072215253130900_B31","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.0907994106","article-title":"Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis","volume":"106","author":"Bieging","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2022072215253130900_B32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2013-07-517649","article-title":"Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma","volume":"123","author":"Fish","year":"2014","journal-title":"Blood."},{"issue":"23","key":"2022072215253130900_B33","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2017-07-796821","article-title":"EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice","volume":"130","author":"Fish","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022072215253130900_B34","doi-asserted-by":"crossref","first-page":"e00548-19","DOI":"10.1128\/mBio.00548-19","article-title":"Two Pathways of p27Kip1 degradation are required for murine lymphoma driven by Myc and EBV latent membrane protein 2A","volume":"10","author":"Sora","year":"2019","journal-title":"MBio."},{"issue":"3","key":"2022072215253130900_B35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/JVI.74.3.1101-1113.2000","article-title":"Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice","volume":"74","author":"Caldwell","year":"2000","journal-title":"J Virol."},{"issue":"20","key":"2022072215253130900_B36","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1093\/emboj\/16.20.6131","article-title":"Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule","volume":"16","author":"Gires","year":"1997","journal-title":"EMBO J."},{"issue":"20","key":"2022072215253130900_B37","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1101\/gad.13.20.2658","article-title":"Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis","volume":"13","author":"Eischen","year":"1999","journal-title":"Genes Dev."},{"issue":"11","key":"2022072215253130900_B38","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/onc.2008.492","article-title":"Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis","volume":"28","author":"Bultema","year":"2009","journal-title":"Oncogene."},{"issue":"26","key":"2022072215253130900_B39","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1182\/blood-2011-02-338434","article-title":"A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma","volume":"118","author":"Bieging","year":"2011","journal-title":"Blood."},{"issue":"8","key":"2022072215253130900_B40","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/onc.2013.28","article-title":"Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2","volume":"33","author":"Walczynski","year":"2014","journal-title":"Oncogene."},{"issue":"4","key":"2022072215253130900_B41","doi-asserted-by":"crossref","first-page":"e00378-18","DOI":"10.1128\/mSphereDirect.00378-18","article-title":"Spleen tyrosine kinase inhibitor TAK-659 prevents splenomegaly and tumor development in a murine model of Epstein-Barr virus-associated lymphoma","volume":"3","author":"Cen","year":"2018","journal-title":"MSphere."},{"issue":"9","key":"2022072215253130900_B42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/bloodadvances.2016000794","article-title":"High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis","volume":"1","author":"Lombardo","year":"2017","journal-title":"Blood Adv."},{"issue":"19","key":"2022072215253130900_B43","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood."},{"issue":"16","key":"2022072215253130900_B44","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2017-02-767335","article-title":"Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets","volume":"130","author":"Bouska","year":"2017","journal-title":"Blood."},{"issue":"12","key":"2022072215253130900_B45","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet."},{"issue":"12","key":"2022072215253130900_B46","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet."},{"issue":"39","key":"2022072215253130900_B47","doi-asserted-by":"crossref","first-page":"63504","DOI":"10.18632\/oncotarget.11531","article-title":"Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human","volume":"7","author":"Eason","year":"2016","journal-title":"Oncotarget."},{"key":"2022072215253130900_B48","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.2147\/CMAR.S269624","article-title":"Characteristics and management of TP53-mutated diffuse large b-cell lymphoma patients","volume":"12","author":"Qin","year":"2020","journal-title":"Cancer Manag Res."},{"issue":"4","key":"2022072215253130900_B49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1535-7163.MCT-10-0833","article-title":"Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt\u2019s lymphoma","volume":"10","author":"Cen","year":"2011","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2022072215253130900_B50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2012.05.003","article-title":"Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A","volume":"95","author":"Dargart","year":"2012","journal-title":"Antiviral Res."},{"issue":"19","key":"2022072215253130900_B51","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1128\/JVI.74.19.9115-9124.2000","article-title":"The LMP2A ITAM is essential for providing B cells with development and survival signals in\u00a0vivo","volume":"74","author":"Merchant","year":"2000","journal-title":"J Virol."},{"issue":"11","key":"2022072215253130900_B52","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1093\/emboj\/18.11.3064","article-title":"Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins","volume":"18","author":"Gires","year":"1999","journal-title":"EMBO J."},{"issue":"23","key":"2022072215253130900_B53","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med."},{"issue":"23","key":"2022072215253130900_B54","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med."},{"issue":"13","key":"2022072215253130900_B55","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2010-08-301556","article-title":"Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes","volume":"117","author":"Piccaluga","year":"2011","journal-title":"Blood."},{"issue":"12","key":"2022072215253130900_B56","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2011.156","article-title":"The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia."},{"issue":"6","key":"2022072215253130900_B57","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1365-2141.2010.08111.x","article-title":"MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma","volume":"149","author":"Robertus","year":"2010","journal-title":"Br J Haematol."},{"issue":"18","key":"2022072215253130900_B58","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1073\/pnas.1701836114","article-title":"Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease","volume":"114","author":"Minamitani","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"issue":"20","key":"2022072215253130900_B59","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1158\/0008-5472.CAN-08-1329","article-title":"Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma","volume":"68","author":"Mori","year":"2008","journal-title":"Cancer Res."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4283\/1909544\/advancesadv2022007695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4283\/1909544\/advancesadv2022007695.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T11:26:39Z","timestamp":1658489199000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4283\/485325\/Latent-membrane-proteins-from-EBV-differentially"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":59,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007695","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}